Surface engineering of porous silicon to optimise therapeutic antibody loading and release

Steven McInnes, Chris Turner, Sameer Al-Bataineh, Marta Leccardi, Yazad Irani, Keryn Williams, Allison Cowin, Nicholas Voelcker

    Research output: Contribution to journalArticlepeer-review

    27 Citations (Scopus)


    The proinflammatory cytokine, tumor necrosis factor-α (TNF-α), is elevated in several diseases such as uveitis, rheumatoid arthritis and non-healing chronic wounds. Adding Infliximab, a chimeric IgG1 monoclonal antibody raised against TNF-α, to chronic wound fluid can neutralise human TNF-α, thereby providing a potential therapeutic option for chronic wound healing. However, to avoid the need for repeated application in a clinical setting, and to protect the therapeutic antibody from the hostile environment of the wound, suitable delivery vehicles are required. Porous silicon (pSi) is a biodegradable high surface area material commonly employed for drug delivery applications. In this study, the use of pSi microparticles (pSi MPs) for the controlled release of Infliximab to disease environments, such as chronic wounds, is demonstrated. Surface chemistry and pore parameters for Infliximab loading are first optimised in pSi films and loading conditions are transferred to pSi MPs. Loading regimens exceeding 60 μg of Infliximab per mg of pSi are achieved. Infliximab is released with zero-order release kinetics over the course of 8 days. Critically, the released antibody remains functional and is able to sequester TNF-α over a weeklong timeframe; suitable for a clinical application in chronic wound therapy.

    Original languageEnglish
    Pages (from-to)4123-4133
    Number of pages11
    JournalJournal of materials chemistry. B
    Issue number20
    Publication statusPublished - 2015


    Dive into the research topics of 'Surface engineering of porous silicon to optimise therapeutic antibody loading and release'. Together they form a unique fingerprint.

    Cite this